江苏艾迪药业集团股份有限公司 2025年度业绩快报公告

Core Viewpoint - The company reported significant improvements in its financial performance for the year 2025, with a notable increase in revenue and a substantial reduction in net losses compared to the previous year [1][2]. Financial Data and Indicators - Total revenue for the reporting period reached 720.67 million yuan, representing a 72.49% increase year-on-year [2][3]. - Operating profit was 47.75 million yuan, marking a turnaround from a loss to profitability [2]. - Total profit amounted to 24.30 million yuan, also indicating a shift from loss to profit [2]. - The net profit attributable to the parent company's owners was -19.73 million yuan, with the loss margin decreasing by 86.02% compared to the previous year [2][3]. - The net profit attributable to the parent company after excluding non-recurring gains and losses was -20.93 million yuan, with a decrease in loss margin of 85.90% year-on-year [2][3]. Operational Performance and Financial Condition - The company's total assets at the end of the reporting period were 1,916.26 million yuan, reflecting a 2.50% increase from the beginning of the period [2]. - Equity attributable to the parent company's owners decreased by 1.67% to 964.48 million yuan [2]. - The increase in revenue was primarily driven by higher income from innovative HIV drugs and the consolidation of Nanda Pharmaceutical's operational data, which contributed approximately 255 million yuan to gross profit [2]. - Sales expenses increased by approximately 92 million yuan due to intensified new drug promotion efforts and the consolidation of Nanda Pharmaceutical's data [2]. - Asset impairment losses decreased by approximately 48 million yuan as market expansion and expectations stabilized [2].